U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 5
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
[_] Check box if no longer subject to Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).
[_] Form 3 Holdings Reported
[_] Form 4 Transactions Reported
________________________________________________________________________________
1. Name and Address of Reporting Person*
Novartis AG
--------------------------------------------------------------------------------
(Last) (First) (Middle)
Lichtstrasse 35
--------------------------------------------------------------------------------
(Street)
CH-4002, Basel, Switzerland
--------------------------------------------------------------------------------
(City) (State) (Zip)
________________________________________________________________________________
2. Issuer Name and Ticker or Trading Symbol
Chiron Corporation/CHIR
________________________________________________________________________________
3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)
________________________________________________________________________________
4. Statement for Month/Year
12/2000
________________________________________________________________________________
5. If Amendment, Date of Original (Month/Year)
________________________________________________________________________________
6. Relationship of Reporting Person to Issuer
(Check all applicable)
[_] Director [X] 10% Owner
[_] Officer (give title below) [_] Other (specify below)
________________________________________________________________________________
7. Individual or Joint/Group Filing
(Check applicable line)
[_] Form filed by one Reporting Person
[X] Form filed by more than one Reporting Person
________________________________________________________________________________
================================================================================
Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned
================================================================================
<TABLE>
<CAPTION>
5. 6.
4. Amount of Owner-
Securities Acquired (A) or Securities ship
Disposed of (D) Beneficially Form: 7.
(Instr. 3, 4 and 5) Owned at End Direct Nature of
2. 3. ----------------------------- of Issuer's (D) or Indirect
1. Transaction Transaction (A) Fiscal Year Indirect Beneficial
Title of Security Date Code Amount or Price (Instr. 3 (I) Ownership
(Instr. 3) (mm/dd/yy) (Instr. 8) (D) and 4) (Instr.4) (Instr. 4)
--------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
--------------------------------------------------------------------------------------------------------------------------------
Common Stock 5,469,770 I Through
Novartis
Pharma AG
--------------------------------------------------------------------------------------------------------------------------------
Common Stock 73,842,852 I Through
Novartis
Biotech
--------------------------------------------------------------------------------------------------------------------------------
Common Stock 7,456 I Through
Novartis
Corporation
--------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------
================================================================================================================================
</TABLE>
* If the form is filed by more than one Reporting Person, see Instruction
4(b)(v).
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
<PAGE>
FORM 5 (continued)
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
================================================================================
<TABLE>
<CAPTION>
9. 10.
Number Owner-
of ship
2. Deriv- of
Conver- 5. 7. ative Deriv- 11.
sion Number of Title and Amount Secur- ative Nature
or Derivative 6. of Underlying 8. ities Secur- of
Exer- Securities Date Securities Price Bene- ity: In-
cise 3. Acquired (A) Exercisable and (Instr. 3 and 4) of ficially Direct direct
Price Trans- 4. or Disposed Expiration Date ---------------- Deriv- Owned (D) or Bene-
1. of action Trans- of (D) (Month/Day/Year) Amount ative at End In- ficial
Title of Deriv- Date action (Instr. 3, ---------------- or Secur- of direct Owner-
Derivative ative (Month/ Code 4 and 5) Date Expira- Number ity Year (I) ship
Security Secur- Day/ (Instr. ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr.
(Instr. 3) ity Year) 8) (A) (D) cisable Date Title Shares 5) 4) 4) 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Explanation of Responses:
Novartis AG is the beneficial owner of a total of 79,320,078 Common Shares of
Chiron Corporation. Of such shares, 5,469,770 shares are owned by Novartis
Pharma AG (a wholly owned subsidiary of Novartis AG), 73,842,852 shares are
owned by Novartis Biotech Partnership, Inc. (an indirect wholly owned
subsidiary of Novartis AG) and 7,456 shares are owned by Novartis Corporation
(an indirect wholly owned subsidiary of Novartis AG).
/s/ Robert L. Thompson, Jr. 1/11/01
--------------------------------------------- -----------------------
**Signature of Reporting Person Date
** Intentional misstatements or omissions of facts constitute Federal Criminal
Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.
Page 2
<PAGE>
Additional Reporting Person: Novartis Pharma AG (a wholly owned subsidiary of
Novartis AG)
Address: Lichtstrasse 35; CH-4002
Basel, Switzerland
Designated Filer: Novartis AG
Issuer & Ticker Symbol: Chiron Corporation/CHIR
Statement for Month/Year: 2000
/s/ Wayne P. Merkelson 1/11/01
---------------------- ------------
Signature of Date
Reporting Person
Additional Reporting Person: Novartis Biotech Partnership, Inc. (an indirect
wholly owned subsidiary of Novartis AG)
Address: 564 Morris Avenue;
Summit, NJ 07901
Designated Filer: Novartis AG
Issuer & Ticker Symbol: Chiron Corporation/CHIR
Statement for Month/Year: 12/2000
/s/ Jeff Benjamin 1/11/01
---------------------- ------------
Signature of Date
Reporting Person
Additional Reporting Person: Novartis Corporation (an indirect wholly owned
subsidiary of Novartis AG)
Address: 564 Morris Avenue;
Summit, NJ 07901
Designated Filer: Novartis AG
Issuer & Ticker Symbol: Chiron Corporation/CHIR
Statement for Month/Year: 12/2000
/s/ Wayne P. Merkelson 1/11/01
---------------------- ------------
Signature of Date
Reporting Person
EDGARLink 7.0 (8/00) Ver. 3.1
